<DOC>
	<DOC>NCT02635360</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.</brief_summary>
	<brief_title>Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Confirmed cervical cancer. Must have adequate organ function. Subject is pregnant. Recurrent cervical cancer. Distant metastases. Malignancy within the last 5 years; basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy is permissable. Subject has had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer. Subject has a immunodeficiency. Known history of HIV, Hepatitis B, Hepatitis C, TB, or inflammatory bowel disease. Hypersensitivity to pembrolizumab or similar drugs. Subject has an active autoimmune disease in the past 2 years. Known history of noninfectious pneumonitis. Subject has an active infection. Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases are permissible. Talk to Study Contact for specifics.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>immunotherapy</keyword>
</DOC>